PSP Research LLC bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,258 shares of the specialty pharmaceutical company’s stock, valued at approximately $554,000. Jazz Pharmaceuticals accounts for 0.5% of PSP Research LLC’s portfolio, making the stock its 6th largest position.
Several other hedge funds also recently made changes to their positions in the company. Cardinal Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 9.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 81 shares during the period. Pinnacle Associates Ltd. lifted its stake in shares of Jazz Pharmaceuticals by 0.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares during the period. Fairbanks Capital Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after acquiring an additional 94 shares during the period. Finally, Danske Bank A S lifted its stake in shares of Jazz Pharmaceuticals by 33.3% in the 4th quarter. Danske Bank A S now owns 400 shares of the specialty pharmaceutical company’s stock worth $68,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.
Jazz Pharmaceuticals Stock Performance
NASDAQ:JAZZ opened at $237.45 on Wednesday. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The firm has a 50-day moving average price of $199.21 and a two-hundred day moving average price of $178.13. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $238.55. The company has a market capitalization of $14.90 billion, a P/E ratio of -11,866.57, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27.
Insider Buying and Selling at Jazz Pharmaceuticals
In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the sale, the senior vice president directly owned 28,728 shares in the company, valued at $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director owned 384,682 shares of the company’s stock, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 74,015 shares of company stock valued at $14,180,486. Corporate insiders own 4.30% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on JAZZ shares. Royal Bank Of Canada raised their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $188.00 to $307.00 in a research note on Tuesday. Raymond James Financial restated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $238.00.
Check Out Our Latest Stock Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
